The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.
The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product, including osteoporosis in postmenopausal women.
The ACR honors excellence in rheumatology. Meet the 2025 Awards of Distinction recipients, ACR Masters & Distinguished Fellows recognized at ACR Convergence 2025.
Meet the 2025 ARP President’s & Merit Award recipients honored for their significant contributions to rheumatology research, education & patient care.
The ACR recognizes 16 members with its highest honor. See the 2025 class of ACR Masters & read their personal reflections on this career milestone.
Meet the 10 clinical & research fellows named 2025 ACR Distinguished Fellows. Learn what this prestigious honor means to them & their work.
The ACR has expert guidance for states applying for the Rural Health Transformation Program, including recommendations on policies designed to improve healthcare delivery, strengthen the workforce and ensure patient access to rheumatology care.
From educating her colleagues to sharing stories of hope & words of encouragement with her patients, pediatric rheumatology resident Adaobi Ugochukwu draws on her own experience with lupus to ensure that patients receive empathetic, compassionate care.
Dr. Marc Hirsch reflects on a career dedicated to advocating for physicians, providing patient-centered care & advancing medical education.